[1]Wiesweg M, et al. Treatment sequences in BRAF-V600-mutant non-small cell lung cancer: First-line targeted therapy versus first-line (chemo-) immunotherapy. 2024 ESMO 1300P.
[2]Russo A, et al. BRAF-mutant metastatic non-small cell lung cancer: Real-world data from the Italian biomarker ATLAS database. 2024 ESMO 1301P.
[3]Lin FP, et al. Phase II trial of vemurafenib (VEM) and cobimetinib (COB) in BRAF V600-mutated solid tumours and first-line (1L) nonsmall cell lung cancer (NSCLC): Australian molecular screening and therapeutics (MoST) substudy 12. 2024 ESMO 623P.
[4]Honma Y, et al. Phase II trial of encorafenib and binimetinib (E+B) in patients (pts) with BRAF-altered advanced solid tumors: Results of E+B cohort in the BELIEVE trial (NCCH1901). 2024 ESMO 621P.
[5]Niu JJ, et al. Resensitization of BRAF-mutated radioactive iodine refractory differentiated thyroid cancer with longer duration of dabrafenib and trametinib. 2024 ESMO 1930P.
[6]Taleb N, et al. Real-world safety of trametinib monotherapy or in combination with dabrafenib in children, adolescents, and young adults with relapsed or refractory low-grade glioma (LGG) and high-grade glioma (HGG). 2024 ESMO 468P.
[7]Wu YL, et al. Matching-Adjusted Indirect Comparison (MAIC) of overall survival (OS) and treatment related adverse events (TRAE) comparing Capmatinib (CAP) with other Mesenchymal-epithelial transition (MET) Inhibitors for treatment of advanced non-small cell lung cancer (aNSCLC) with MET Exon 14 skipping mutations. 2024 WCLC EP.12D.05.
[8]Wu YL, et al. Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer. J Clin Oncol. 2018;36(31):3101-3109.
[9]Aggarwal V, et al. MET Point Mutations as the Mechanism of Resistance to EGFR-TKI Therapy: A Case Report of MET H1094Y-Mediated Resistance to Osimertinib Overcome by Capmatinib and a Systematic Review. 2024 WCLC EP.12A.39.